We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Supporters campaigned for years for access to cystic fibrosis drug Orkambi Leah Farrell/
cost effective

'The system is not adequate': Government sets up new way to judge medicines for rare diseases

Many drugs for rare diseases have been ruled as not “cost-effective” under existing criteria.

HEALTH MINISTER SIMON Harris has confirmed that a new committee is being set up to decide whether or not medicines for extremely rare diseases get approved by the HSE.

It is usually the job of the National Centre for Pharmacoeconomics (NCPE) to make a judgement on whether or not a drug is “cost-effective” but advocates for patients have said that their methods of evaluation are unsuited to medicines for rare diseases.

When it comes to rare diseases, the medicines are usually very costly and their price often exceeds the criteria set out by the NCPE and HSE.

Recent examples of medicines that faced lengthy waits to get approved include cystic fibrosis drug Orkambi and Respreeza, a drug for patients with Alpha-1 (genetic emphysema).

The latter drug has yet to be approved, and campaigners hoping to make the drug available for patients will hold a vigil outside the HSE head office tomorrow.

Harris was asked today by deputy Tommy Broughan about access to a drug called Kuvan, for patients with phenylketonuria, in the Dáil today.

0148 HSE Report for Better GP and Primary Care_90529145 Sasko Lazarov / Sasko Lazarov / /

He said: “I have heard parents campaigning for this drug make a very valid point.  They are concerned the system we have in place for assessing drugs for rare diseases is not adequate.

A new committee called the rare diseases medicinal product technology review committee has been established by the NCPE.  The terms of reference of the committee have been finalised and its responsibilities include the review of proposals for funding of new products for rare diseases or expanded indications for existing products for rare diseases.

On the issue of Kuvan, Harris said that the process of trying to make the drug available for the patients who need it has not ended, and that the HSE is still negotiating a price with the makers of the drug.

“When it comes to drug negotiations pressure is rightly put on me and on the HSE,” he said.

Harris added that he would make an announcement in the coming weeks on how Ireland could formalise cooperation with other countries to get better access to new medicines for debilitating conditions.

Read: ‘Inappropriate and unethical’: Varadkar backs life-saving lung disease drug for some users after HSE fails to fund it

Read: ‘Oh, that’s just the price’: €11 difference in cost of same medication in two Dublin pharmacies

Your Voice
Readers Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel